Sobi : Interim Report, January - March 2012
(Thomson Reuters ONE) -
Geoffrey McDonough, CEO: "The first quarter marks a solid beginning for 2012
with consistent growth across our product business lines. We finalized two
significant transactions with Pfizer and made an important revision of the
agreement regarding the acquisition of Arexis and have no remaining obligations
towards the sellers for any development program including Kiobrina®. We are
focusing on creating a strong base for growing our commercial portfolio and to
improve operational efficiency. The first phase in the establishment of the new
subsidiary in the US was finalized during the quarter. In addition we are very
pleased to have received approval for our Pediatric Investigation Plans for both
Kineret® in new indications and for Orfadin® in a liquid formulation. At
approval the new Orfadin formulation would also extend the orphan designation in
Europe through 2017."
* Total revenues declined by 6% to SEK 506.7 M (537.4), and by 3% adjusted for
currency and discontinued products.
* Product revenues [1]())rose by 10% to SEK 365.6 M (332.1), and by 16%
adjusted for currency effects and discontinued products, mainly driven by
Core Products.
* Gross margin declined to 51% (53%), mainly due to costs for the transfer of
Kineret production and the divestment of the co-promotion rights for ReFacto
AF®/BeneFIX® as of 15 February 2012.
* Proceeds of SEK 307.5 M from the divestment of the co-promotion rights
included in operating profit.
* Operating profit also includes non-recurring items of SEK -34 M related to
the amended purchase agreement with the sellers of Arexis on 30 March 2012.
* The previously published outlook for 2012 remains unchanged.
Telephone Conference
The interim report for the first quarter 2012 will be presented by CEO Geoffrey
McDonough, COO Alan Raffensperger and CFO Lars Sandström at a media and analyst
telephone conference.
Time: Thursday, 26 April 2012 at 2 p.m. (CET)
To participate in the telephone conference, please call:
SE: +46 (0)8 505 597 72
UK: +44 (0)207 750 99 50
US: + 1 866 676 58 70
A recorded version will be available afterwards at www.sobi.com under Investors
& Media/Audio cast. Slides used in the presentation will also be available on
the web site under Investors & Media/Presentations.
For more information, please contact:
Lars Sandström, CFO, Telephone: +46 8 697 26 33
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 26 April 2012 at 8.30 CET.
--------------------------------------------------------------------------------
[1]) Product revenues include Core Products and Partner Products.
Complete Interim Report, January - March 2012:
http://hugin.info/134557/R/1606155/508993.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1606155]
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2012 - 08:31 Uhr
Sprache: Deutsch
News-ID 139464
Anzahl Zeichen: 3823
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi : Interim Report, January - March 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
